Document is current
Any future updates will be listed below
-
Authors
Hunker, Avery C. https://orcid.org/0000-0003-0508-3637
Mich, John K. https://orcid.org/0000-0002-1626-1139
Taskin, Naz
Torkelson, Amy https://orcid.org/0000-0002-9465-4202
Cardenas, Trangthanh
Lalanne, Jean-Benoît
Mahoney, Joseph T.
Bertagnolli, Darren
Chakka, Anish Bhaswanth
Chakrabarty, Rushil https://orcid.org/0000-0003-1722-8557
Donadio, Nicholas P.
Ferrer, Rebecca
Gasperini, Molly
Goldy, Jeff
Guzman, Junitta
Jin, Kelly https://orcid.org/0000-0003-2393-6461
Khem, Shannon
Kutsal, Rana https://orcid.org/0009-0008-7190-6498
Martinez, Refugio A.
Newman, Dakota
Pena, Nick
Rimorin, Christine
Rocha, Dana
Shapovalova, Nadiya V.
Tieu, Michael
Weed, Natalie https://orcid.org/0000-0003-0891-0327
Zhou, Thomas
Hodge, Rebecca https://orcid.org/0000-0002-5784-9668
Yao, Shenqin https://orcid.org/0000-0003-2992-4752
Shendure, Jay https://orcid.org/0000-0002-1516-1865
Smith, Kimberly A. https://orcid.org/0000-0002-3142-1970
Lein, Ed S. https://orcid.org/0000-0001-9012-6552
Tasic, Bosiljka https://orcid.org/0000-0002-6861-4506
Levi, Boaz P. https://orcid.org/0000-0002-8346-872X
Ting, Jonathan T. https://orcid.org/0000-0001-8266-0392
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 8 April 2026
First Online: 28 April 2026
Competing interests
: Authors J.K.M. and B.P.L. declare equity in EpiCure Therapeutics, Inc. JS is a scientific advisory board member, consultant and/or co-founder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Sixth Street Capital, Prime Medicine, Somite Therapeutics and Pacific Biosciences. The Allen Institute is the applicant on multiple published WIPO PCT patent applications related to synthetic enhancer AAV constructs for therapeutic applications. These applications pertain to the design and use of enhancer AAVs for cell type-specific gene delivery described in this manuscript. The inventors on these applications include E.S.L., B.P.L., R.A.M., J.K.M., J.T.T. (2023/245013A2); E.S.L., B.P.L., R.A.M., J.K.M. (2024/163796A2); E.S.L., B.P.L., J.K.M., B.T., J.T.T. (2022/036255A1); E.S.L., B.P.L., J.K.M., B.T., J.T.T. (2024/163914A2); J.T.T., B.P.L., B.T., J.K.M., E.S.L. (2020/168279A2); E.S.L., B.P.L., J.K.M., B.T., and J.T.T. (2022/103859A1); and E.S.L., B.P.L., J.K.M., B.T., and J.T.T. (2021/248085A2). The remaining authors declare no competing interests.
